Iveric Bio to Present at the UBS Global Healthcare Conference 2022

Rhea-AI Summary

IVERIC bio (NASDAQ: ISEE) announced that President Pravin U. Dugel, M.D., will participate in a fireside chat at the UBS Global Healthcare Conference on May 23, 2022, at 10:45 a.m. Eastern Time. The event will be accessible via a live webcast on the Investor Events section of IVERIC's website, with an archived replay available for 30 days post-conference. IVERIC bio focuses on developing innovative treatments for retinal diseases, aiming to improve patient outcomes in conditions like age-related macular degeneration.

PARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 on Monday, May 23, 2022, at 10:45 a.m. Eastern Time.

Investors and the general public are invited to access the live webcast of the fireside chat on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the on-demand presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.

About Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the “Risk Factors” section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005721/en/

Investors:

Kathy Galante

Senior Vice President, Investor Relations

kathy.galante@ivericbio.com

or

Media:

Jeannie Neufeld

Senior Director, Public Relations and Communications

jeannie.neufeld@ivericbio.com

Source: IVERIC bio, Inc.

FAQ

When will IVERIC bio's fireside chat take place?

IVERIC bio's fireside chat will occur on May 23, 2022, at 10:45 a.m. Eastern Time.

How can I listen to IVERIC bio's fireside chat?

You can access the live webcast of IVERIC bio's fireside chat on their website in the Investor Events section.

What is the focus of IVERIC bio as a company?

IVERIC bio focuses on developing novel treatments for retinal diseases with significant unmet medical needs.

Is there a replay available for IVERIC bio's fireside chat?

Yes, an archived replay of the presentation will be available on IVERIC bio's website for at least 30 days after the conference.

Who is participating in the UBS Global Healthcare Conference for IVERIC bio?

Pravin U. Dugel, M.D., President of IVERIC bio, will participate in the UBS Global Healthcare Conference.